ArticleKidney research and clinical practice2025
Characteristics of glomerulonephritis with dominant C1q precipitation compared to corresponding glomerulonephritis without C1q staining on immunofluorescent examination.
Article in Kidney research and clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance and renal outcomes of C1q nephropathy (C1qN) are unclear; therefore, the implications of C1qN as a new pathological entity are uncertain. We compared the clinical characteristics of glomerulonephritis reclassified into cases that meet the definition of C1qN and glomerulonephritis not included in the definition of C1qN.
methodsIn total, 21,697 patients who underwent native kidney biopsy at 18 hospitals throughout Korea between 1979 and 2018 were retrospectively enrolled. A total of 77 patients were selected from the group that met the definition of C1qN after reclassification; however, six patients were excluded because of secondary systemic disease. Characteristics of pathological findings classified into C1qN, without C1q stain, and with nondominant C1q stain that did not fulfill the criteria for C1qN were compared.
resultsNo differences in clinicopathological findings and incidence of ESRD were evident (matched by age and sex) between glomerulonephritis cases reclassified into the group that met the definition of C1qN and those without C1q staining. Decreased proteinuria in patients with membranous nephropathies reclassified into the group that met the definition of C1qN was the only significant finding. Immunoglobulins showed higher intensity on immunofluorescence staining of the group that met the definition of C1qN. Additionally, C3 intensity was higher in reclassified immunoglobulin A nephropathy and membranous nephropathies.
conclusionOverall, reclassification into the group that met the definition of C1qN did not indicate a different clinicopathological identity. C1q activation and presumed classical complement pathway activation in kidney tissues in C1qN could not be confirmed. Hence, further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.